<DOC>
	<DOC>NCT02265393</DOC>
	<brief_summary>This is a 2-part study of OTO-104 in subjects with unilateral Meniere's disease in the United Kingdom. The first part is a randomized, placebo-controlled study comparing the safety profile of 2 injections of OTO-104 or placebo spaced 3 months apart. The second part is an open-label extension where all subjects will receive an additional 2 intratympanic injections of OTO-104 spaced 3 months apart. Each subject will participate on the study for a total of 1 year.</brief_summary>
	<brief_title>A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom</brief_title>
	<detailed_description />
	<mesh_term>Meniere Disease</mesh_term>
	<criteria>Inclusion Criteria includes, but is not limited to: Subject has a diagnosis of definite unilateral Meniere's disease. Subject agrees to maintain their current standard of care treatments for Meniere's disease while onstudy. Exclusion Criteria includes, but is not limited to: Subject is pregnant or lactating. Subject has a history of immunodeficiency disease. Subject has a history of previous endolymphatic sac surgery. Subject has a history of previous use of intratympanic gentamicin in the affected ear. Subject has a history of drop attacks. Subject has experienced an adverse reaction to intratympanic injection of steroids.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>